Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07181356

Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction

At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

A total of 2146 patients with AMI are expected included as the research objects and randomly divided into experimental group and control group with 1073 cases in each group. After admission, Patients in the experimental group received everyday RIPC of upper limbs to the end of follow-up.The control group is a blank control and undergoes conventional medical procedures. Routine blood indexes, ultrasound, electrocardiogram, were detected On the day of admission. 12 months post- discharge, the incidence of MACCE(include Cardiovascular death, non-fatal acute myocardial infarction, stent thrombosis, revascularization, stroke, admission due to heart failure and the above composite events were independent components) and Poce(All deaths, all strokes, all myocardial infarction, or all revascularization events)will recorded by telephone follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction"

Exclusion criteria

  • The patients could not tolerate RIPC or RIPerC
  • Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases
  • The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively
  • severe liver dysfunction (bilirubin > 20 mmol / L, prothrombin time > 2.0 ratio)
  • Severe renal insufficiency (GFR < 30 ml / min / 1.73 m2);
  • patients taking nicorandil and other drugs affecting microcirculation
  • pregnant

Treatment and study plan

RIPerC

Other

Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

RIPC

Other

Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

Primary outcomes

  1. Rate of MACCEs

    Time frame: 12 months after discharge

    MACCE(include Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke, admission due to heart failure )

Secondary outcomes

  1. Rate of Cardiovascular death events

    Time frame: 12 months after discharge

    Rate of Cardiovascular death events

  2. Rate of non-fatal acute myocardial infarction events

    Time frame: 12 months after discharge

    Rate of non-fatal acute myocardial infarction events

  3. Rate of revascularization events

    Time frame: 12 months after discharge

    Rate of revascularization events

  4. Rate of stroke events

    Time frame: 12 months after discharge

    Rate of stroke events

  5. Rate of admission due to heart failure events

    Time frame: 12 months after discharge

    Rate of admission due to heart failure events

  6. Rate of all all-cause death events

    Time frame: 12 months after discharge

    Rate of all all-cause death events

Study contacts

Contact information is provided by the study sponsor or research team.

GUO QUAN

CONTACT

[email protected]

15670510031

Muwei LI

CONTACT

[email protected]

13838083966

Sponsors and collaborators

Lead sponsor

Henan Institute of Cardiovascular Epidemiology

Other

Registry information

Acronym: L-RICP-AMI

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Sep 18, 2025
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.